Literature DB >> 28875989

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Christina A Brezing1,2, Frances R Levin1,2.   

Abstract

Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.

Entities:  

Mesh:

Year:  2017        PMID: 28875989      PMCID: PMC5719115          DOI: 10.1038/npp.2017.212

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  103 in total

1.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

2.  Marijuana withdrawal among adults seeking treatment for marijuana dependence.

Authors:  A J Budney; P L Novy; J R Hughes
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

3.  Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.

Authors:  A M Weinstein; H Miller; I Bluvstein; E Rapoport; S Schreiber; R Bar-Hamburger; M Bloch
Journal:  Am J Drug Alcohol Abuse       Date:  2014-01       Impact factor: 3.829

Review 4.  Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.

Authors:  Patrick Vermersch
Journal:  Expert Rev Neurother       Date:  2011-04       Impact factor: 4.618

5.  Addiction severity index profile of persons who reenter treatment for substance use disorders.

Authors:  Hélène Simoneau; Serge Brochu
Journal:  Subst Abus       Date:  2017-07-19       Impact factor: 3.716

6.  Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.

Authors:  Jose M Trigo; Alexandra Soliman; Gregory Staios; Lena Quilty; Benedikt Fischer; Tony P George; Jürgen Rehm; Peter Selby; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

Review 7.  Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis.

Authors:  Edward J Mills; Ping Wu; Ian Lockhart; Kristian Thorlund; Milo Puhan; Jon O Ebbert
Journal:  Ann Med       Date:  2012-08-06       Impact factor: 4.709

8.  Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

Authors:  Dayong Lee; Ryan Vandrey; Damodara R Mendu; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-09-14       Impact factor: 3.345

Review 9.  Pharmacotherapy for cannabis dependence: how close are we?

Authors:  Ryan Vandrey; Margaret Haney
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Differential roles for cortical versus sub-cortical noradrenaline and modulation of impulsivity in the rat.

Authors:  Abigail Benn; Emma S J Robinson
Journal:  Psychopharmacology (Berl)       Date:  2016-10-15       Impact factor: 4.530

View more
  40 in total

1.  Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.

Authors:  Dustin C Lee; Nicolas J Schlienz; Erica N Peters; Robert H Dworkin; Dennis C Turk; Eric C Strain; Ryan Vandrey
Journal:  Drug Alcohol Depend       Date:  2018-11-15       Impact factor: 4.492

2.  Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Evan Herrmann; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin; Frances R Levin
Journal:  Addict Biol       Date:  2018-04-16       Impact factor: 4.280

Review 3.  Cannabis use and cannabis use disorder.

Authors:  Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall
Journal:  Nat Rev Dis Primers       Date:  2021-02-25       Impact factor: 52.329

4.  Cannabis and Cannabinoids: From Synapse to Society.

Authors:  Margaret Haney; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2018-01       Impact factor: 7.853

5.  The Changing Landscape of Substance Use Disorders.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

6.  Mu-opioid antagonism in the treatment of cannabis use disorder

Authors:  Oussama Kebir; Xavier Laqueille; Fayçal Mouaffak
Journal:  J Psychiatry Neurosci       Date:  2020-03-01       Impact factor: 6.186

Review 7.  Care of the Patient Using Cannabis.

Authors:  Arthur Robin Williams; Kevin P Hill
Journal:  Ann Intern Med       Date:  2020-11-03       Impact factor: 25.391

8.  Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.

Authors:  Kristen R Trexler; Sara R Nass; Molly S Crowe; Joshua D Gross; Margaret S Jones; Austin W McKitrick; David P Siderovski; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2018-07-07       Impact factor: 4.492

9.  Pharmacotherapy for the Treatment of Cannabis Use Disorder.

Authors:  Christina A Brezing; Frances R Levin
Journal:  Ann Intern Med       Date:  2020-08-04       Impact factor: 25.391

10.  Cannabis and the Current State of Treatment for Cannabis Use Disorder.

Authors:  Arthur Robin Williams; Kevin P Hill
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.